Blocking inflammasome activation mitigates hepatic inflammation and fibrosis in mice bearing NASH [8], suggesting that inhibition of NLRP3 inflammasome activation is a suitable pharmacological strategy against NASH. The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatohepatitis.